Release Date: 18/06/18 13:14 Summary: 4.2 cents per share takeover offer from Hancock Price Sensitive: Yes Download Document 141.47KB Download
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%